Outcome Predictors for Intestinal Behçet’s Disease
2
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
Behçet’s disease (BD) is a multisystem inflammatory disorder that presents as recurrent oral and genital ulcers in conjunction with other dermatological and ocular manifestations. The prevalence of BD is higher in Middle and East Asia than in Western countries. Intestinal BD is a specific subtype of BD, characterized by intestinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory bowel disease, intestinal BD exhibits a fluctuating disease course with repeated episodes of relapse and remission that necessitate adequate maintenance therapy after achievement of clinical remission. Medical treatment of intestinal BD is largely empirical since well-controlled studies have been difficult to perform due to the heterogeneity and rarity of the disease. To date, 5-aminosalicylic acid, systemic corticosteroids, and immunosuppressants have been used anecdotally to treat intestinal BD. The clinical course of intestinal BD shows considerable variability,and the exact point at which more potent agents such as immunosuppressants should be used has not yet been elucidated. Given the difficulty in predicting which patients will experience complicated disease courses and the fact that these drugs are related with certain risk resulting from immunosuppression, proper identification of prognostic factors in intestinal BD may allow physicians to implement tailored medical therapy and individualized patient monitoring based on risk stratification. In this review, the impact of baseline characteristics on the long-term course of intestinal BD, prognostic factors during various medical therapies, and outcome predictors related to surgery will be discussed.
Abstract
Behçet’s disease (BD) is a multisystem inflammatory disorder that presents as recurrent oral and genital ulcers in conjunction with other dermatological and ocular manifestations. The prevalence of BD is higher in Middle and East Asia than in Western countries. Intestinal BD is a specific subtype of BD, characterized by intestinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory bowel disease, intestinal BD exhibits a fluctuating disease course with repeated episodes of relapse and remission that necessitate adequate maintenance therapy after achievement of clinical remission. Medical treatment of intestinal BD is largely empirical since well-controlled studies have been difficult to perform due to the heterogeneity and rarity of the disease. To date, 5-aminosalicylic acid, systemic corticosteroids, and immunosuppressants have been used anecdotally to treat intestinal BD. The clinical course of intestinal BD shows considerable variability,and the exact point at which more potent agents such as immunosuppressants should be used has not yet been elucidated. Given the difficulty in predicting which patients will experience complicated disease courses and the fact that these drugs are related with certain risk resulting from immunosuppression, proper identification of prognostic factors in intestinal BD may allow physicians to implement tailored medical therapy and individualized patient monitoring based on risk stratification. In this review, the impact of baseline characteristics on the long-term course of intestinal BD, prognostic factors during various medical therapies, and outcome predictors related to surgery will be discussed.
참고문헌 (42)
- Kobayashi K, "Development of consensus statements for the diagnosis and management of intestinal Behçet’s disease using a modified Delphi approach", J Gastroenterol, 42, pp.737~745 (2007)
- Sakane T, "Behçet’s disease", N Engl J Med, 341, pp.1284~1291 (1999)
- Suzuki Kurokawa M, "Behçet’s disease", Clin Exp Med, 4, pp.10~20 (2004)
- Dilsen N, "History and development of Behçet’s disease", Rev Rhum Engl Ed, 63, pp.512~519 (1996)
- Kaklamani VG, "Behçet’s Disease", Semin Arthritis Rheum, 27, pp.197~217 (1998)
- Bayraktar Y, "Gastrointestinal manifestations of Behçet’s disease", J Clin Gastroenterol, 30, pp.144~154 (2000)
- Cheon JH, "Behçet’s disease: gastrointestinal involvement, In Behçet’s syndrome", pp.165~188 (2010), Springer
- Shimizu T, "Behçet disease (Behçet syndrome)", Semin Arthritis Rheum, 8, pp.223~260 (1979)
- Lakhanpal S, "Pathologic features of Behçet’s syndrome: a review of Japanese autopsy registry data", Hum Pathol, 16, pp.790~795 (1985)
- Gürler A, "Clinical manifestations of Behçet’s disease: an analysis of 2147 patients", Yonsei Med J, 38, pp.423~427 (1997)
- Lee CR, "Colonoscopic findings in intestinal Behçet’s disease", Inflamm Bowel Dis, 7, pp.243~249 (2001)
- Mizushima Y, "Diagnostic criteria for Behçet’s disease in 1987, and guideline for treating Behçet’s disease", Saishin Igaku, 43, pp.391~393 (1988)
- Criteria for diagnosis of Behçet’s disease, "International Study Group for Behçet’s Disease", Lancet, 335, pp.1078~1080 (1990)
- Shin SJ, "Chronological changes in the systemic manifestations of intestinal Behçet’s disease and their significance in diagnosis", Int J Colorectal Dis, 25, pp.1371~1376 (2010)
- Cheon JH, "Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers", Am J Gastroenterol, 104, pp.2492~2499 (2009)
- Ebert EC, "Gastrointestinal manifestations of Behçet’s disease", Dig Dis Sci, 54, pp.201~207 (2009)
- Jung YS, "Clinical course of intestinal Behçet’s disease during the first five years", Dig Dis Sci, 58, pp.496~503 (2013)
- Jung YS, "Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behçet’s disease", Inflamm Bowel Dis, 18, pp.1064~1071 (2012)
- Kim DK, "Clinical manifestations and course of intestinal Behçet’s disease: an analysis in relation to diaesase subtypes", Intest Res, 3, pp.48~54 (2005)
- Choi IJ, "Long-term clinical course and prognostic factors in intestinal Behçet’s disease", Dis Colon Rectum, 43, pp.692~700 (2000)
- Chung MJ, "Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease", J Clin Gastroenterol, 44, pp.e116~e122 (2010)
- Kim JS, "Prediction of the clinical course of Behçet’s colitis according to macroscopic classification by colonoscopy", Endoscopy, 32, pp.635~640 (2000)
- Yim SM, "Mucosal healing predicts the long term prognosis of intestinal Behçet’s Disease", Intest Res, 11(1), pp.43~ (2013)
- Pineton de Chambrun G, "Clinical implications of mucosal healing for the management of IBD", Nat Rev Gastroenterol Hepatol, 7, pp.15~29 (2010)
- Choi CH, "Anti-Saccharomyces cerevisiae antibody in intestinal Behçet’s disease patients: relation to clinical course", Dis Colon Rectum, 49, pp.1849~1859 (2006)
- Naganuma M, "Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet’s disease", Am J Gastroenterol, 95, pp.2848~2851 (2000)
- Shin SJ, "Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal Behçet’s disease", Dig Dis Sci, 56, pp.812~818 (2011)
- Jung YS, "Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease", J Clin Gastroenterol, 46, pp.e38~e45 (2012)
- Park JJ, "Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget’s disease", Gastroenterology, 138(1), pp.S698~S699 (2010)
- Jung YS, "Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behçet’s disease", Inflamm Bowel Dis, 18, pp.750~757 (2012)
- Yamashita N, "Role of gammadelta T lymphocytes in the development of Behçet’s disease", Clin Exp Immunol, 107, pp.241~247 (1997)
- Hassard PV, "Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report", Gastroenterology, 120, pp.995~999 (2001)
- Travis SP, "Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody", Gut, 49, pp.725~728 (2001)
- Kram MT, "Behçet’s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case", Dis Colon Rectum, 46, pp.118~121 (2003)
- Mussack T, "Successful treatment of cervical esophageal perforation in Behçet’s disease with drainage operation and infliximab", Am J Gastroenterol, 98, pp.703~704 (2003)
- Byeon JS, "Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet’s disease: report of a case", Dis Colon Rectum, 50, pp.672~676 (2007)
- Ju JH, "Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab", Clin Rheumatol, 26, pp.1383~1385 (2007)
- Naganuma M, "Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease", Inflamm Bowel Dis, 14, pp.1259~1264 (2008)
- Iwata S, "Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease", Mod Rheumatol, 21, pp.184~191 (2011)
- Lee JH, "Efficacy of Infliximab in Intestinal Behçet’s Disease: A Korean Multicenter Retrospective Study", Inflamm Bowel Dis (2013)
- Moon CM, "Prediction of free bowel perforation in patients with intestinal Behçet’s disease using clinical and colonoscopic findings", Dig Dis Sci, 55, pp.2904~2911 (2010)
- Jung YS, "Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behçet’s disease", wInflamm Bowel Dis, 17, pp.1594~1602 (2011)